CCS1477 for Solid Cancers
Trial Summary
What is the purpose of this trial?
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.
Will I have to stop taking my current medications?
You may need to stop taking certain medications before joining the trial. Specifically, you must stop taking statins and any strong inhibitors or inducers of CYP3A4. If you are on chemotherapy, investigational agents, or other anti-cancer drugs, you need to stop them at least 14 days before the trial starts.
What makes the drug CCS1477 unique for treating solid cancers?
CCS1477, also known as Inobrodib, is unique because it targets specific proteins involved in cancer cell growth and survival, potentially offering a novel approach compared to traditional chemotherapy or other targeted therapies. Its mechanism of action and potential to be combined with immune-based therapies could provide new treatment options for patients with solid cancers.12345
Research Team
Johann de Bono, MD
Principal Investigator
Royal Marsden NHS Foundation Trust
Eligibility Criteria
This trial is for adults with advanced prostate, breast, non-small cell lung cancer or solid tumors. Participants must have specific genetic markers indicating a potential response to treatment and meet health criteria like good organ function and performance status. They should not have severe diseases, unresolved toxicities from past therapies, or be taking certain drugs that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CCS1477 as monotherapy or in combination with other drugs for advanced solid/metastatic tumours
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CCS1477
Find a Clinic Near You
Who Is Running the Clinical Trial?
CellCentric Ltd.
Lead Sponsor